Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2000;36:325-329

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, U.
Right arrow Articles by Shimada, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, U.
Right arrow Articles by Shimada, K.
Related Collections
Right arrow Pathophysiology
Right arrow Cell signalling/signal transduction
Right arrow Acute coronary syndromes
Right arrow Lipid and lipoprotein metabolism
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2000;36:325.)
© 2000 American Heart Association, Inc.


Scientific Contributions

Fluvastatin Inhibits Matrix Metalloproteinase-1 Expression in Human Vascular Endothelial Cells

Uichi Ikeda; Masahisa Shimpo; Ruri Ohki; Hideko Inaba; Masafumi Takahashi; Keiji Yamamoto; Kazuyuki Shimada

From the Department of Cardiology, Jichi Medical School, Tochigi, Japan.

Correspondence to Uichi Ikeda, MD, PhD, Department of Cardiology, Jichi Medical School, Minamikawachi-Machi, Tochigi 329-0498, Japan. E-mail uikeda{at}jichi.ac.jp

Abstract—Matrix metalloproteinase-1 (MMP-1), also called interstitial collagenase, may play an important role in the pathogenesis of atherosclerosis and atherosclerotic plaque rupture. We investigated the effects of fluvastatin on MMP-1 expression in human vascular endothelial cells (ECs). The addition of fluvastatin decreased the basal MMP-1 levels in the culture media of ECs in a time-dependent (0 to 48 hours) and dose-dependent (10-8 to 10-5 mol/L) manner. On the other hand, fluvastatin did not affect tissue inhibitor of metalloproteinase-1 levels. Collagenolytic activity in conditioned media of ECs was also dose-dependently reduced by fluvastatin. The effect of fluvastatin on MMP-1 expression was completely reversed in the presence of mevalonate or geranylgeranyl-pyrophosphate, but not in the presence of squalene. Inhibition of Rho by C3 exoenzyme also significantly decreased MMP-1 expression in ECs. Our findings revealed that fluvastatin decreases MMP-1 expression in human vascular ECs through inhibition of Rho.


Key Words: atherosclerosis • nitric oxide • extracellular matrix • collagen




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Y. Alvarez, C. Municio, S. Alonso, J. A. S. Roman, M. S. Crespo, and N. Fernandez
Cyclooxygenase-2 Induced by Zymosan in Human Monocyte-Derived Dendritic Cells Shows High Stability, and Its Expression Is Enhanced by Atorvastatin
J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 987 - 994.
[Abstract] [Full Text] [PDF]


Home page
VASC ENDOVASCULAR SURGHome page
K. I. Paraskevas, C. D. Liapis, G. Hamilton, and D. P. Mikhailidis
Are Statins an Option in the Management of Abdominal Aortic Aneurysms?
Vascular and Endovascular Surgery, May 1, 2008; 42(2): 128 - 134.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
V. Zaca, S. Rastogi, M. Imai, M. Wang, V. G. Sharov, A. Jiang, S. Goldstein, and H. N. Sabbah
Chronic Monotherapy With Rosuvastatin Prevents Progressive Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure
J. Am. Coll. Cardiol., August 7, 2007; 50(6): 551 - 557.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Oktem, I. Esinler, D. Eroglu, N. Haberal, N. Bayraktar, and H. B. Zeyneloglu
High-dose atorvastatin causes regression of endometriotic implants: a rat model
Hum. Reprod., May 1, 2007; 22(5): 1474 - 1480.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Ferri, G. Colombo, C. Ferrandi, E. W. Raines, B. Levkau, and A. Corsini
Simvastatin Reduces MMP1 Expression in Human Smooth Muscle Cells Cultured on Polymerized Collagen by Inhibiting Rac1 Activation
Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1043 - 1049.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 290 - 297.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. J. M. Greer, A. K. Kakkar, J. W. Elrod, L. J. Watson, S. P. Jones, and D. J. Lefer
Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure
Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2743 - H2751.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
E Hothersall, C McSharry, and N C Thomson
Potential therapeutic role for statins in respiratory disease.
Thorax, August 1, 2006; 61(8): 729 - 734.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Ichihara, A. Noda, K. Nagata, K. Obata, J. Xu, G. Ichihara, S. Oikawa, S. Kawanishi, Y. Yamada, and M. Yokota
Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure
Cardiovasc Res, February 15, 2006; 69(3): 726 - 735.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
S Van Doornum, G McColl, and I P Wicks
Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis
Ann Rheum Dis, December 1, 2004; 63(12): 1571 - 1575.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
U. Schonbeck and P. Libby
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. B Jones, D. C Sane, and D. M Herrington
Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome
Cardiovasc Res, October 1, 2003; 59(4): 812 - 823.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Z. Luan, A. J. Chase, and A. C. Newby
Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages
Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 769 - 775.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. Axisa, I. M. Loftus, A. R. Naylor, S. Goodall, L. Jones, P. R.F. Bell, M. M. Thompson, and C. Napoli
Prospective, Randomized, Double-Blind Trial Investigating the Effect of Doxycycline on Matrix Metalloproteinase Expression Within Atherosclerotic Carotid Plaques * Editorial Comment
Stroke, December 1, 2002; 33(12): 2858 - 2864.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Werle, U. Schmal, K. Hanna, and J. Kreuzer
MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells
Cardiovasc Res, November 1, 2002; 56(2): 284 - 292.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Delbosc, J.-P. Cristol, B. Descomps, A. Mimran, and B. Jover
Simvastatin Prevents Angiotensin II-Induced Cardiac Alteration and Oxidative Stress
Hypertension, August 1, 2002; 40(2): 142 - 147.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
R. Dechend, D. Muller, J. K. Park, A. Fiebeler, H. Haller, and F. C. Luft
Statins and angiotensin II-induced vascular injury
Nephrol. Dial. Transplant., March 1, 2002; 17(3): 349 - 353.
[Full Text] [PDF]


Home page
Circ. Res.Home page
Z. S. Galis and J. J. Khatri
Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: The Good, the Bad, and the Ugly
Circ. Res., February 22, 2002; 90(3): 251 - 262.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Weis, C. Heeschen, A. J. Glassford, and J. P. Cooke
Statins Have Biphasic Effects on Angiogenesis
Circulation, February 12, 2002; 105(6): 739 - 745.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. A. Kreisberg and A. Oberman
Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437.
[Full Text] [PDF]


Home page
Circ. Res.Home page
G. J. Blake and P. M. Ridker
Novel Clinical Markers of Vascular Wall Inflammation
Circ. Res., October 26, 2001; 89(9): 763 - 771.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Dechend, A. Fiebeler, J.-K. Park, D. N. Muller, J. Theuer, E. Mervaala, M. Bieringer, D. Gulba, R. Dietz, F. C. Luft, et al.
Amelioration of Angiotensin II-Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor
Circulation, July 31, 2001; 104(5): 576 - 581.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Bellosta, M. Canavesi, E. Favari, L. Cominacini, G. Gaviraghi, R. Fumagalli, R. Paoletti, and F. Bernini
Lalsoacidipine Modulates the Secretion of Matrix Metalloproteinase-9 by Human Macrophages
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 736 - 743.
[Abstract] [Full Text]


Home page
HypertensionHome page
F. C. Luft
Workshop: Mechanisms and Cardiovascular Damage in Hypertension
Hypertension, February 1, 2001; 37(2): 594 - 598.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Hayashidani, H. Tsutsui, T. Shiomi, N. Suematsu, S. Kinugawa, T. Ide, J. Wen, and A. Takeshita
Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction
Circulation, February 19, 2002; 105(7): 868 - 873.
[Abstract] [Full Text] [PDF]